Aromatase, cyclooxygenase 2, HER-2/neu, and P53 as prognostic factors in endometrioid endometrial cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 670-676

  Jongen, Vincent H W M ^a   Briët, Justine M ^a   De Jong, Renske A ^a   Joppe, Erna ^a   Ten Hoor, Klaske A ^a   Boezen, H M ^a   Evans, Dean B ^b   Hollema, Harry ^c   Van Der Zee, Ate G J ^a   Nijman, Hans W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Aromatase; COX 2; Endometrioid endometrial cancer; HER 2 neu; P53

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIOID ENDOMETRIUM CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TISSUE MICROARRAY; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE; CARCINOMA, ENDOMETRIOID; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67651055469     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a47c25     Document Type: Article

References (41)

1. Brueggemeier RW, Diaz-Cruz ES. Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches. Minerva Endocrinol. 2006;31:13-26.
2. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635.
3. Subbaramaiah K, Norton L, Gerald W, et al. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem. 2002;277: 18649-18657.
4. Subbaramaiah K, Howe LR, Port ER, et al. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2 dependent mechanism. Cancer Res. 2006;66: 5504-5511.
5. Watanabe K, Sasano H, Harada N, et al. Aromatase in human endometrial carcinoma and hyperplasia. Am J Pathol. 1995;146: 491-500.
6. Jongen VHWM, Thijssen JHH, Hollema H, et al. Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer? Int J Gynecol Cancer. 2005;15:529-536.
7. Jongen VHWM, Hollema H, van der Zee AGJ, et al. Aromatase in the context of breast and endometrial cancer. A review. Minerva Endocrinol. 2006;31:47-60.
8. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Pathol. 2004;23:409-410.
9. Sung CJ, Zheng Y, Quddus MR, et al. P53 as a significant prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2000;10: 119-127.
10. Hachiguda T, Fukuda K, Uchiyama M, et al. Immunohistochemical study of P53 expression in endometrial carcinomas: correlation with markers of proliferating cells and clinicopathological features. Int J Gynecol Cancer. 1993;3:363.
11. Powell B, Soong R, Grieu F, et al. P53 protein overexpression is a prognostic factor of poor survival in stage I endometrial carcinoma. Int J Oncol. 1999;14:175-179.
12. Soong R, Knowles S, Williams KE, et al. Overexpression of P53 protein is an independent prognostic factor in human endometrial carcinoma. Br J Cancer. 1996;74:562-567.
13. Jeon YT, Kang SB, Hang DH, et al. Cyclooxygenase-2 and P53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1538-1542.
14. Ferrandina G, Ranalletti FO, Gallota V, et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), P53, ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005;98:383-389.
15. Briet JM, Hollema H, Reesink N, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol. 2005;96:799-804.
16. Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 2001;10:657-662.
17. Fowler JM, Ramirez N, Cohn DE, et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol. 2005;192:1262-1271.
18. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell-lines: opportunities and limitations. Lab Invest. 2001;81:1331-1338.
19. Hendriks Y, Franken P, Diersen JW, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol. 2003;162: 469-477.
20. Sasano H, Edwards DP, Anderson TJ, et al. Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report. J Steroid Biochem Mol Biol. 2003;86:239-244.
21. Sasano H, Anderson TJ, Silverberg SG, et al. The validation of new aromatase monoclonal antibodies for immunohistochemistry-a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol. 2005;95:35-39.
22. Nijhuis ER, Nijman HW, Oien KA, et al. Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. J Clin Pathol. 2007;60:824-830.
23. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24: 2376-2385.
24. Ala-Fossi SL, Maenpaa J, Aine R, et al. Ovarian testosterone secretion during perimenopause. Maturitas. 1998;29:239-245.
25. Jongen VHWM, Sluijmer AV, Heineman MJ. The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer. Maturitas. 2002;43:77-85.
26. Sasano H, Kaga K, Sato S, et al. Aromatase P450 gene expression in endometrial carcinoma. Br J Cancer. 1996;74:1541-1544.
27. Yamamoto T, Kitawaki J, Urabe M, et al. Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Molec Biol. 1993;44:463-468.
28. Pathirage N, Di Nezza LA, Salmonsen LA, et al. Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertil Steril. 2006;86:469-472.
29. Segawa T, Shozu M, Murakami K, et al. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. Clin Cancer Res. 2005;11:2188-2194.
30. Coronado PJ, Vidart JA, Lopez-Asenjo JA, et al. P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol. 2001;98:103-108.
31. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999;18:138-143.
32. Mariani A, Sebo TJ, Katzmann JA, et al. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature. Anticancer Res. 2005;25:2921-2927.
33. Fujiwaki R, Iida K, Kanasaki H, et al. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol. 2002;33:213-219.
34. Richards JA, Brueggemeier RW. Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab. 2003;88:2810-2816.
35. Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol. 2002;80:203-212.
36. Orejuela F, Ramondetta LM, Smith J, et al. Estrogen and progesterone receptors and cyclooxygenbase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol. 2005;97:483-488.
37. Ferrandina G, Legge F, Ranelleti F, et al. Cyclooxygenase-2 expression in endometrial carcinoma. Correlation with clinicopathologic parameters and clinical outcome. Cancer. 2002;95:801-807.
38. Landen CR Jr, Mathur SP, Richardson MS, et al. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003;188:1174-1176.
39. Brodie AM, Lu Q, Long BJ, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol. 2001;79:41-47.
40. Brueggemeier RW, Quinn AL, Parrett ML, et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 1999;140:27-35.
41. Macwhinnie N, Managhan H. The use of p53, PTEN and C-erb-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. In J Gynecol Cancer. 2004;14:938-946.